Medicina
Cure8 research brief
Why This Matters
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking cessation counseling in IBD management.
Who Should Pay Attention
Adults with Crohn’s disease or ulcerative colitis, patients currently on or considering anti-TNF therapy, clinicians managing IBD, and patients who smoke.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study suggests active cigarette smoking may reduce the chance of clinical response/remission on anti-TNF drugs and is linked to needing more treatment courses. This comes from a single-center retrospective analysis reported in the article abstract; it does not establish causation but supports advising smoking cessation as part of IBD care.
Practical note: If you smoke and are starting or on anti-TNF therapy, discuss smoking cessation with your IBD team. Clinicians may consider smoking status when counseling patients about expectations for anti-TNF effectiveness and treatment planning.
Keep In Mind
This is a retrospective cohort from a single dataset with variable sample sizes across drug classes; findings for non–anti-TNF agents were limited by smaller numbers. The abstract-level content summarizes study findings but does not provide full methodological detail or peer commentary.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationMedicina
AuthorsSofia Cinque, Maria Laura Annunziata, Antonella Bianchi +7 more
InstitutionIRCCS Policlinico San Donato
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedSep 23, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.